[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma. It was administered at a dose of 1.2-1.5 g/body/day for 5 consecutive days every 3-4 weeks, and the patients treated over 2 courses were registered in our trial. Eleven patients had not received prior chemotherapy. Results achieved were as follows: PR in one patient, NC in 9 patients, and PD in 10 patients. The response rate was 5% and the median survival time was 17 weeks. Toxic effects included anorexia (80%), nausea and vomiting (65%), alopecia (20%), mental disturbance (20%), granulocytopenia (20%), thrombocytopenia (5%), and no renalurological disturbance. We concluded that ifosfamide was not effective for chemotherapy of advanced pancreatic carcinoma.
Fujiki
T
T
Dept. of Gastroenterology, Saitama Cancer Center Hospital.
Futatsuki
K
K
Akazawa
S
S
Yamamoto
K
K
Kanda
Y
Y
Yamato
A
A
Terashi
K
K
Suda
Y
Y
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D014839:Vomiting / Q000139:chemically induced
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide